Aurinia Stock Dips as Traders Eye Lupkynis Data
Aurinia Pharmaceuticals shares fell 0.9% to $15.21 in late morning Nasdaq trading Friday, underperforming the broader biotech sector. Investors focused on Lupkynis sales and the upcoming June 3 shareholder meeting, with no new company news released. The company relies on Lupkynis as its only approved drug and faces competition from GSK’s Benlysta and Genentech’s Gazyva.